First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
7/22/26
LIGAND PHARMACEUTICALS (LGNDZ)
Wednesday
1:27 AM
Thesis: Ligand Pharmaceuticals: the story is balanced — Partner pipeline progression - FDA approvals or Phase 3 trial results for programs using Ligand technologies trigger…
★ Analysts see FY2027 revenue reaching $376M — +29.7% growth in a single year.
What Moves the Stock
1Partner pipeline progression - FDA approvals or Phase 3 trial results for programs using Ligand technologies trigger milestone payments and future royalty streams
2New licensing agreements - Announcements of technology partnerships with upfront fees and potential milestone/royalty terms
3Royalty revenue growth from existing commercial products - Quarterly sales performance of key royalty-generating drugs like Kyprolis (multiple myeloma)
4M&A activity - Acquisitions of additional royalty portfolios or technology platforms to expand revenue base
5Partner company developments - Commercial success or setbacks at major partners (Amgen, Takeda, Merck, others) directly impact royalty flows
6Royalty revenue from commercial products using Captisol solubilization technology and OmniAb antibody platforms (estimated 60-70% of revenue)
7License fees and milestone payments from new technology partnerships and development stage achievements (estimated 20-30%)
8Material sales of Captisol enabling formulation to pharmaceutical partners (estimated 10-15%)
growth - Investors are attracted to the high-margin, asset-light royalty model with potential for compounding cash flows as partner pipeline…
Rising rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples for long-duration…
Watch on earnings: Quarterly royalty revenue by product and therapeutic area to track commercial portfolio performance, Number of partner programs in Phase 2/3 trials and regulatory review as leading indicators of future milestone payments, New licensing deal announcements with disclosed economics (upfront fees, milestone potential, royalty rates).
One Sentence Summary:
Ligand Pharmaceuticals: the story is balanced — partner pipeline progression - fda approvals or phase 3 trial results for programs using ligand technologies trigger milestone payments.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.